Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade) [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Insider buying and strategic ATC investments indicate market confidence; however, clinician adoption and post-market data remain potential risks. Upgrading investment recommendation to "Buy" based on favorable regulatory outlook, solid liquidity, and promising commercial strategies, though due diligence is advised. At a Glance Navigating through regulatory delays and internal investment shifts, Iovance Biotherapeutics NASDAQ: IOVA ) continues to position itself as a frontrunner in T-cell therapies for solid tumors. Since my last "Hold" recommendation , the FDA's extension of lifileucel's Priority Review to February 2024 signaled not a roadblock but a procedural hiccup. This delay, paradoxically, may provide time for further fine-tuning of its market strategy, already underscored by significant Authorized Treatment Centers (ATC) investments and payer engagements. Insider confidence is palpable, with a recent $25M share acquisition by an Iovance director, boosting stock value. Wi
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website